

InVirtuoLabs

The next-generation laboratory for drug design

Rare Diseases

- **400 Million** affected globally
- **95%** with no treatment


2.4
Billion
CHF¹


to bring a single drug to market





Generative AI is about to reshape the way we design drugs






100%

Increase of the
success rate



400%

Speed of discovery





Our **Founding** Team



Gianvito Grasso
PhD
Chief Executive Officer



Sertac Yeltekin
Chief Operating Officer




Francesco Gentile
PhD
AI for Chemistry



Claudio Pietra
Chief Scientific Officer



Demet Olesen
Chief Commercial Officer




Stefano Muscat
PhD
Molecular Modelling




Pre-seed Round
Convertible Loan Agreement

Raised: 2.7M CHF
Closed: Q4 2024

Equity Round: 5 M CHF
Closing: Q1 2026



Accelerating the development of life-saving medications



Get In Touch

Gianvito Grasso

Email: gianvito@invirtuolabs.com